Skip to content

US · PALI · BIOTECHNOLOGY

Palisade Bio, Inc. (PALI) intrinsic value and stock valuation

$0.84as of 2026-11-21 · Mkt cap 367.99M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Palisade Bio, Inc. DCF and intrinsic value

InvestorsCraft values PALI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PALI’s statements →

Palisade Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Denver, CA 80237 palisadebio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-16.78M
20112025
Free cash flow
-$-10.85M
20112025
Total equity
$129.4M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$250K$0.00$0.00
Operating income-$-18.06M-$-14.86M-$-13.07M-$-15.72M-$-41.85M
Net income-$-16.78M-$-14.44M-$-12.3M-$-14.26M-$-26.62M
EPSd-$-301.42K-$-10.17M-$-26.74M-$-16.2M-$-2.66B
Operating cash flow-$-10.85M-$-12.19M-$-11.13M-$-13.36M-$-14.77M
Capital expenditure$0.00$0.00-$0.00-$-10K$0.00
Free cash flow-$-10.85M-$-12.19M-$-11.14M-$-13.37M-$-14.77M
Total assets$134.3M$10.9M$14.1M$15.8M$12.5M
Total debt$70K$170K$370K$400K$200K
Net debt-$-133.31M-$-9.65M-$-12.06M-$-11.98M-$-10.3M
Total equity$129.4M$7.49M$11.3M$12.5M$7.37M
Cash and short-term investments$133.4M$9.82M$12.4M$12.4M$10.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$250K$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$250K$0.00$0.00
Research and development expenses$10.2M$9.06M$6.89M$6.55M$2.43M
Selling, general and administrative expenses$7.86M$5.8M$6.2M$8.76M$9.31M
Other expenses$0.00$0.00$230K$410K$30.1M
Operating expenses$18.1M$14.9M$13.3M$15.7M$41.9M
Cost and expenses$18.1M$14.9M$13.3M$15.7M$41.9M
Interest income$0.00$0.00$0.00$10K$0.00
Interest expense$10K$10K$10K$10K$2.4M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-16.77M-$-14.42M-$-12.28M-$-14.24M-$-24.22M
Operating income-$-18.06M-$-14.86M-$-13.07M-$-15.72M-$-41.85M
Total other income/expenses, net$1.27M$420K$770K$1.46M$15.2M
Income before tax-$-16.78M-$-14.44M-$-12.3M-$-14.26M-$-26.62M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-16.78M-$-14.44M-$-12.3M-$-14.26M-$-26.62M
Weighted average shares outstanding$55.7M$1.42M$460K$880K$10K
Weighted average diluted shares outstanding$55.7M$1.42M$460K$880K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$133.4M$9.82M$12.4M$12.4M$10.5M
Net receivables$260K$20K$150K$1.44M$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$134.2M$10.5M$13.3M$14.7M$11.5M
Property, plant and equipment, net$0.00$90K$210K$310K$110K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$60K$30K$0.00$30K$0.00
Total non-current assets$120K$390K$720K$1.03M$1.01M
Total assets$134.3M$10.9M$14.1M$15.8M$12.5M
Accounts payable$770K$1.1M$700K$1.76M$1.52M
Short-term debt$70K$170K$280K$190K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.64M$3.24M$2.59M$3.01M$2.5M
Long-term debt$0.00$0.00$90K$210K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$330K$150K$150K$270K$2.65M
Capital lease obligations$0.00$90K$210K$320K$110K
Total liabilities$4.96M$3.39M$2.74M$3.28M$5.15M
Common stock$1.59M$30K$90K$30K$0.00
Retained earnings-$-152.72M-$-135.94M-$-121.51M-$-109.19M-$-94.64M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$129.4M$7.49M$11.3M$12.5M$7.37M
Total investments$60K$30K$0.00$30K$0.00
Total debt$70K$170K$370K$400K$200K
Net debt-$-133.31M-$-9.65M-$-12.06M-$-11.98M-$-10.3M
Cash flow statement
20252024202320222021
Net income-$-16.78M-$-14.44M-$-12.3M-$-14.26M-$-26.62M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$3.96M$650K$620K$1.03M$1.89M
Change in working capital$1.64M$1.39M$400K$1.25M-$-4.76M
Accounts receivable$0.00$0.00$0.00$0.00$80K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$620K$820K-$-490K$400K-$-2.4M
Net cash provided by operating activities-$-10.85M-$-12.19M-$-11.13M-$-13.36M-$-14.77M
Investments in property, plant and equipment$0.00$0.00-$0.00-$-10K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00-$-50K
Net cash used for investing activities$0.00$0.00-$0.00-$-10K-$-50K
Common stock issued$135.3M$8.44M$9.42M$14.4M$5.21M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$134.4M$9.58M$11.2M$15.3M$24.6M
Net change in cash$123.6M-$-2.61M$50K$1.89M$9.78M
Cash at end of period$133.4M$9.85M$12.5M$12.4M$10.5M
Operating cash flow-$-10.85M-$-12.19M-$-11.13M-$-13.36M-$-14.77M
Capital expenditure$0.00$0.00-$0.00-$-10K$0.00
Free cash flow-$-10.85M-$-12.19M-$-11.14M-$-13.37M-$-14.77M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Palisade Bio, Inc.

        Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

        CEO
        J. D. Finley
        Employees
        14
        Beta
        1.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Palisade Bio, Inc. (PALI)?

        InvestorsCraft does not currently publish an intrinsic value for PALI. How the IC value is calculated.

        Is PALI undervalued?

        InvestorsCraft does not publish an undervaluation signal for PALI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.